Assessment of the prescription of antidepressant drugs in elderly nursing home patients: A clinical and laboratory follow-up investigation

Journal of Clinical Psychopharmacology

Volumn 28, Issue 4, 2008, Pages 424-431

  Chermá, Maria D ^a,d   Löfgren, Ulla Britt ^b   Almkvist, Göran ^c   Hallert, Claes ^b   Bengtsson, Finn ^a  

^a LINKÖPING UNIVERSITY   (Sweden)

^b Central Research Unit

^c Primary Health Care in Eastern Östergötland   (Sweden)

^d LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CITALOPRAM; CLOMIPRAMINE; CYANOCOBALAMIN; CYTOCHROME P450; DINORCITALOPRAM; DRUG METABOLITE; FLUOXETINE; FUROSEMIDE; LACTULOSE; MACROGOL; MIRTAZAPINE; NORCITALOPRAM; OXAZEPAM; PARACETAMOL; PAROXETINE; SERTRALINE; UNCLASSIFIED DRUG; VENLAFAXINE; ZOLPIDEM;

AGED; AGED HOSPITAL PATIENT; ARTICLE; BIPOLAR DISORDER; COMPULSION; CONSTIPATION; CREATININE CLEARANCE; DEMENTIA; DEPRESSION; DIZZINESS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG INDICATION; DRUG METABOLISM; DRUG MONITORING; DRUG USE; DYSPEPSIA; DYSTHYMIA; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; NURSING HOME PATIENT; PANIC; POLYPHARMACY; PRESCRIPTION; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; SWEDEN; XEROSTOMIA; BLOOD; CLINICAL TRIAL; HOME FOR THE AGED; MULTICENTER STUDY; NURSING HOME; STATISTICS;

AGED; AGED, 80 AND OVER; ANTIDEPRESSIVE AGENTS; DEPRESSION; DRUG MONITORING; DRUG UTILIZATION REVIEW; FEMALE; FOLLOW-UP STUDIES; HOMES FOR THE AGED; HUMANS; MALE; NURSING HOMES; PRESCRIPTIONS, DRUG; SWEDEN;

EID: 54449099519     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/JCP.0b013e31817d79eb     Document Type: Article

References (49)

1. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet. 1997;349:1498-1504.
2. Palsson S, Skoog I. The epidemiology of affective disorders in the elderly: a review. Int Clin Psychopharmacol. 1997;12(suppl 7):S3-S13.
3. Whooley MA, Browner WS. Association between depressive symptoms and mortality in older women. Study of Osteoporotic Fractures Research Group. Arch Intern Med. 1998;158:2129-2135.
4. Gump BB, Matthews KA, Eberly LE, et al. Depressive symptoms and mortality in men: results from the Multiple Risk Factor Intervention Trial. Stroke. 2005;36:98-102.
5. Lasser RA, Sunderland T. Newer psychotropic medication use in nursing home residents. J Am Geriatr Soc. 1998;46:202-207.
6. Spina E, Scordo MG. Clinically significant drug interactions with anti-depressants in the elderly. Drugs Aging. 2002;19:299-320.
7. Giron MS, Fastbom J, Winblad B. Clinical trials of potential antidepressants: to what extent are the elderly represented: a review Int J Geriatr Psychiatry. 2005;20:201-217.
8. Peveler R, Kendrick T, Buxton M, et al. A randomised controlled trial to compare the cost-effectiveness of tricyclic antidepressants, selective serotonin reuptake inhibitors and lofepramine. Health Technol Assess. 2005;9:1-134.
9. World Health Organization. Anatomical Therapeutic Chemical Classifivation System. Oslo, Norway: WHO; 2003.
10. Brett MA, Dierdorf HD, Zussman BD, et al. Determination of paroxetine in human plasma, using high-performance liquid chromatography with fluorescence detection. J Chromatogr. 1987;419:438-444.
11. Reis M, Aberg-Wistedt A, Agren H, et al. Serum disposition of sertraline, N-desmethylsertraline and paroxetine: a pharmacokinetic evaluation of repeated drug concentration measurements during 6 months of treatment for major depression. Hum Psychopharmacol. 2004;19:283-291.
12. Reis M, Lundmark J, Bjork H, et al. Therapeutic drug monitoring of racemic venlafaxine and its main metabolites in an everyday clinical setting. Ther DrugMonit. 2002;24:545-553.
13. Carlsson B, Olsson G, Reis M, et al. Enantioselective analysis of citalopram and metabolites in adolescents. Ther Drug Monit. 2001;23:658-664.
14. Reis M, Prochazka J, Sitsen A, et al. Inter- and intraindividual pharmacokinetic variations of mirtazapine and its N-demethyl metabolite in patients treated for major depressive disorder: a 6-month therapeutic drug monitoring study. Ther Drug Monit. 2005;27:469-477.
15. Lundmark J, Reis M, Bengtsson F. Serum concentrations of fluoxetine in the clinical treatment setting. Ther DrugMonit. 2001;23:139-147.
16. Zackrisson AL, Lindblom B. Identification of CYP2D6alleles by single nucleotide polymorphism analysis using pyrosequencing. Eur Clin Pharmacol. 2003;59:521-526.
17. Soderback E, Zackrisson AL, Lindblom B, et al. Determination of CYP2D6gene copy number by pyrosequencing. Clin Chem. 2005;51:522-531.
18. Eriksson S, Berg LM, Wadelius M, et al. Cytochrome P450 genotyping by multiplexed real-time dna sequencing with pyrosequencing technology. Assay DrugDev Technol. 2002;1:49-59.
19. Spina E, de Leon J. Metabolic drug interactions with newer antipsychotics: a comparative review. Basic Clin Pharmacol Toxicol. 2007;100:4-22.
20. Venkatakrishnan K, Greenblatt DJ, von Moltke LL, et al. Five distinct human cytochromes mediate amitriptyline N-demethylation in vitro: dominance of CYP 2C19and 3A4. J Clin Pharmacol. 1998; 38:112-121.
21. Nielsen KK, Flinois JP, Beaune P, et al. The biotransformation of clomipramine in vitro, identification of the cytochrome P450s responsible for the separate metabolic pathways. J Pharmacol Exp Ther. 1996; 277:1659-1664.
22. Bengtsson F. Therapeutic drug monitoring of psychotropic drugs. TDM "nouveau." Ther Drug Monit. 2004;26:145-151.
23. Lundmark J, Scheel Thomsen I, Fjord-Larsen T, et al. Paroxetine: pharmacokinetic and antidepressant effect in the elderly. Acta Psychiatr Scand Suppl. 1989;350:76-80.
24. Lundmark J, Reis M, Bengtsson F. Therapeutic drug monitoring of sertraline: variability factors as displayed in a clinical setting. Ther Drug Monit. 2000;22:446-454.
25. Baumann P, Hiemke C, Ulrich S, et al. The AGNP-TDM expert group consensus guidelines: therapeutic drug monitoring in psychiatry. Pharmacopsychiatry. 2004;37:243-65.
26. Reis M, Lundmark J, Bengtsson F. Therapeutic drug monitoring of racemic citalopram: a 5-year experience in Sweden, 1992-1997. Ther Drug Monit. 2003;25:183-191.
27. Kirchheiner J, Nickchen K, Bauer M, et al. Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Mol Psychiatry. 2004;9:442-473.
28. Fredricson Overo K. Kinetics of citalopram in test animals; drug exposure in safety studies. Prog Neuropsychopharmacol Biol Psychiatry. 1982;6:297-309.
29. Ruths S, Straand J, Nygaard HA. Psychotropic drug use in nursing homes-diagnostic indications and variations between institutions. Eur J Clin Pharmacol. 2001;57:523-528.
30. Djernes JK. Prevalence and predictors of depression in populations of elderly: a review. Acta Psychiatr Scand. 2006;113:372-387.
31. Spina E, Scordo MG, D'Arrigo C. Metabolic drug interactions with new psychotropic agents. Fundam Clin Pharmacol. 2003;17:517-538.
32. Veehof L, Stewart R, Haaijer-Ruskamp F, et al. The development of polypharmacy. A longitudinal study. Fam Pract. 2000;17:261-267.
33. Seymour RM, Routledge PA. Important drug-drug interactions in the elderly. Drugs Aging. 1998;12:485-494.
34. Mangoni AA, Jackson SH. Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. Br JClin Pharmacol. 2004;57:6-14.
35. Hu KT, Matayoshi A, Stevenson FT. Calculation of the estimated creatinine clearance in avoiding drug dosing errors in the older patient. Am J Med Sci. 2001;322:133-136.
36. Charlier C, Broly F, Lhermitte M, et al. Polymorphisms in the CYP 2D6gene: association with plasma concentrations of fluoxetine and paroxetine. Ther Drug Monit. 2003;25:738-742.
37. Whyte EM, Romkes M, Mulsant BH, et al. CYP2D6genotype and venlafaxine-XR concentrations in depressed elderly. Int J Geriatr Psychiatry. 2006;21:542-549.
38. Pacher P, Ungvari Z. Selective serotonin-reuptake inhibitor anti- depressants increase the risk of falls and hip fractures in elderly people by inhibiting cardiovascular ion channels. Med Hypotheses. 2001;57:469-471.
39. Gray SL, Lai KV, Larson EB. Drug-induced cognition disorders in the elderly: incidence, prevention and management. Drug Saf. 1999;21:101-122.
40. Swan A. Antidepressants in older persons. Am Fam Physician. 2006;74:1503.
41. Degner D, Grohmann R, Kropp S, et al. Severe adverse drug reactions of antidepressants: results of the German multicenter drug surveillance program AMSP. Pharmacopsychiatry. 2004;37(suppl 1):S39-S45.
42. van Walraven C, Mamdani MM, Wells PS, et al. Inhibition of serotonin reuptake by antidepressants and upper gastrointestinal bleeding in elderly patients: retrospective cohort study. BMJ. 2001;323:655-658.
43. Spigset O. Adverse reactions of selective serotonin reuptake inhibitors: reports from a spontaneous reporting system. Drug Saf. 1999;20:277-287.
44. Dalfen AK, Stewart DE. Who develops severe or fatal adverse drug reactions to selective serotonin reuptake inhibitors? Can J Psychiatry. 2001;46:258-263.
45. Mann K, Hiemke C, Schmidt LG, et al. Appropriateness of therapeutic drug monitoring for antidepressants in routine psychiatric inpatient care. Ther Drug Monit. 2006;28:83-88.
46. Fastbom J, Schmidt I. Shortages in the treatment of depression of the elderly in nursing homes in Stockholm. Diagnosis is based on flimsy ground, follow up performed early. Lakartidningen. 2004;101:3683-3684, 3686-3688.
47. Kragh A. Two out of three persons living in nursing homes for the elderly are treated with at least ten different drugs. A survey of drug prescriptions in the northeastern part of Skane. Lakartidningen. 2004;101:994-996, 999.
48. Ulfvarson J, Adami J, Wredling R, et al. Controlled withdrawal of selective serotonin reuptake inhibitor drugs in elderly patients in nursing homes with no indication of depression. Eur JClin Pharmacol. 2003;59:735-740.
49. Lofgren UB, Rosenqvist U, Lindstrom T, et al. Diabetes control in Swedish community dwelling elderly: more often tight than poor. J Intern Med. 2004;255:96-101.